Paola Cappello

Dr. Paola Cappello

Department of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Turin, Italy
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MKMegan M. Kaneda
Megan M. Kaneda
Paola CappelloPaola Cappello
Paola Cappello
ANAbraham V. Nguyen
Abraham V. Nguyen
NRNatacha Ralainirina
Natacha Ralainirina
CHChanae R. Hardamon
Chanae R. Hardamon
JVJudith A. Varner
Judith A. Varner
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a low 5-year survival rate, yet new immunotherapeutic modalities may offer hope for this and other intractable cancers. Here, we report that inhibitory targeting of PI3Kγ, a key macrophage lipid kinase, stimulates antitumor immune responses, leading to improved survival and responsiveness to standard-of-care chemotherapy in animal models of PDAC. PI3Kγ selectively drives immunosuppressive transcriptional programming in macrophages that inhibits adaptive immune responses and promotes tumor cell invasion and desmoplasia in PDAC. Blockade of PI3Kγ in PDAC-bearing mice reprograms tumor-associated macrophages to stimulate CD8+ T-cell–mediated tumor suppression and to inhibit tumor cell invasion, metastasis, and desmoplasia. These data indicate the central role that macrophage PI3Kγ plays in PDAC progression and demonstrate that pharmacologic inhibition of PI3Kγ represents a new therapeutic modality for this devastating tumor type. Significance: We report here that PI3Kγ regulates macrophage transcriptional programming, leading to T-cell suppression, desmoplasia, and metastasis in pancreas adenocarcinoma. Genetic or pharmacologic inhibition of PI3Kγ restores antitumor immune responses and improves responsiveness to standard-of-care chemotherapy. PI3Kγ represents a new therapeutic immune target for pancreas cancer. Cancer Discov; 6(8); 870–85. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 803

24 February 2011 in The FEBS Journal
Verified
Journal Article
Closed access
PDF file
MCMichela Capello
Michela Capello
SBSammy Ferri Borgogno
Sammy Ferri Borgogno
Paola CappelloPaola Cappello
Paola Cappello
Francesco NovelliFrancesco Novelli
Francesco Novelli

2 April 2016 in OncoImmunology
Verified
Journal Article
Open access
GCGiovanni Francesco Castino
Giovanni Francesco Castino
NCNina Cortese
Nina Cortese
GCGiovanni Capretti
Giovanni Capretti
SSSimone Serio
Simone Serio
GCGiuseppe Di Caro
Giuseppe Di Caro
FMFederica Marchesi
Federica Marchesi
B-cell responses are emerging as critical regulators of cancer progression. In this study, we investigated the role of B lymphocytes in the microenvironment of human pancreatic ductal adenocarcinoma (PDAC), in a retrospective consecutive series of 104 PDAC patients and in PDAC preclinical models. Immunohistochemical analysis revealed that B cells occupy two histologically distinct compartments in human PDAC, either scatteringly infiltrating (CD20-TILs), or organized in tertiary lymphoid tissue (CD20-TLT). Only when retained within TLT, high density of B cells predicted longer survival (median survival 16.9 mo CD20-TLThi vs. 10.7 mo CD20-TLTlo; p = 0.0085). Presence of B cells within TLT associated to a germinal center (GC) immune signature, correlated with CD8-TIL infiltration, and empowered their favorable prognostic value. Immunotherapeutic vaccination of spontaneously developing PDAC (KrasG12D-Pdx1-Cre) mice with α-enolase (ENO1) induced formation of TLT with active GCs and correlated with increased recruitment of T lymphocytes, suggesting induction of TLT as a strategy to favor mobilization of immune cells in PDAC. In contrast, in an implanted tumor model devoid of TLT, depletion of B cells with an anti-CD20 antibody reinstated an antitumor immune response. Our results highlight B cells as an essential element of the microenvironment of PDAC and identify their spatial organization as a key regulator of their antitumor function. A mindfully evaluation of B cells in human PDAC could represent a powerful prognostic tool to identify patients with distinct clinical behaviors and responses to immunotherapeutic strategies.

14 August 2018 in Circulation
Verified
Journal Article
Closed access
PDF file
MLMingchuan Li
Mingchuan Li
VSValentina Sala
Valentina Sala
MSMaria Chiara De Santis
Maria Chiara De Santis
JCJames Cimino
James Cimino
Paola CappelloPaola Cappello
Paola Cappello
AGAlessandra Ghigo
Alessandra Ghigo
Background: Anthracyclines, such as doxorubicin (DOX), are potent anticancer agents for the treatment of solid tumors and hematologic malignancies. However, their clinical use is hampered by cardiotoxicity. This study sought to investigate the role of phosphoinositide 3-kinase γ (PI3Kγ) in DOX-induced cardiotoxicity and the potential cardioprotective and anticancer effects of PI3Kγ inhibition. Methods: Mice expressing a kinase-inactive PI3Kγ or receiving PI3Kγ-selective inhibitors were subjected to chronic DOX treatment. Cardiac function was analyzed by echocardiography, and DOX-mediated signaling was assessed in whole hearts or isolated cardiomyocytes. The dual cardioprotective and antitumor action of PI3Kγ inhibition was assessed in mouse mammary tumor models. Results: PI3Kγ kinase-dead mice showed preserved cardiac function after chronic low-dose DOX treatment and were protected against DOX-induced cardiotoxicity. The beneficial effects of PI3Kγ inhibition were causally linked to enhanced autophagic disposal of DOX-damaged mitochondria. Consistently, either pharmacological or genetic blockade of autophagy in vivo abrogated the resistance of PI3Kγ kinase-dead mice to DOX cardiotoxicity. Mechanistically, PI3Kγ was triggered in DOX-treated hearts, downstream of Toll-like receptor 9, by the mitochondrial DNA released by injured organelles and contained in autolysosomes. This autolysosomal PI3Kγ/Akt/mTOR/Ulk1 signaling provided maladaptive feedback inhibition of autophagy. PI3Kγ blockade in models of mammary gland tumors prevented DOX-induced cardiac dysfunction and concomitantly synergized with the antitumor action of DOX by unleashing anticancer immunity. Conclusions: Blockade of PI3Kγ may provide a dual therapeutic advantage in cancer therapy by simultaneously preventing anthracyclines cardiotoxicity and reducing tumor growth.

15 February 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CRCecilia Roux
Cecilia Roux
SJSoode Moghadas Jafari
Soode Moghadas Jafari
RSRahul Shinde
Rahul Shinde
GDGordon Duncan
Gordon Duncan
DCDavid W. Cescon
David W. Cescon
CGChiara Gorrini
Chiara Gorrini
Significance: Immunotherapies targeting the programmed death-1 (PD-1) and its ligand PD-L1 have recently been combined with standard chemotherapy to potentiate the treatment of solid tumors, including triple negative breast cancer (TNBC). Reactive oxygen species (ROS) have been directly linked to the cytotoxic effects of chemotherapy. Here we report that ROS induced either by chemotherapy (paclitaxel) or antioxidant depletion induce PD-L1 expression in macrophages. PD-L1 positive macrophages have immune-suppressive and angiogenic properties that interfere with the efficacy of paclitaxel in vivo. Indeed, PD-L1 blockade reverts this effect and synergizes with paclitaxel to reduce tumor growth. Our work reveals a pathway that further supports the importance of combining taxane and PD-L1 inhibitors as promising anticancer strategy in TNBC.

17 December 2015 in Clinical Science
Verified
Journal Article
Closed access
PDF file
SRSimona Rolla
Simona Rolla
EAElisa Alchera
Elisa Alchera
CIChiara Imarisio
Chiara Imarisio
VBValentina Bardina
Valentina Bardina
GVGuido Valente
Guido Valente
RCRita Carini
Rita Carini
The mechanisms responsible for the evolution of steatosis toward non-alcoholic steato-hepatitis (NASH) and fibrosis are not completely defined. This study evaluated the role of CD4+ T-helper (Th) cells in this process. We analyzed the infiltration of different subsets of CD4+Th cells in C57BL/6 mice fed with a methione-choline deficient (MCD) diet, which is a model reproducing all phases of human NASH progression. There was an increase in Th17 cells at the beginning of NASH development and at the NASH/fibrosis transition, whereas levels of Th22 cells peaked between the first and the second expansion of Th17 cells. An increase in the production of IL-6, TNFa, TGFβ and CCL20 accompanied the changes in Th17/22 cells. Livers of IL-17-/- mice were protected from NASH development and characterized by an extensive infiltration of Th22 cells. In vitro , IL-17 exacerbated the JNK-dependent mouse hepatocyte lipotoxicity induced by palmitate. IL-22 prevented lipotoxicity through phosphatidylinositol-3-kinase-mediated inhibition of JNK but did not play a protective role in the presence of IL-17, which upregulated the phosphatidylinositol-3-kinase/Akt inhibitor PTEN. Consistently, livers of IL-17-/- mice fed with the MCD diet displayed decreased activation of JNK, reduced expression of PTEN and increased phosphorylation of Akt compared to livers of wild type mice. Hepatic infiltration of Th17 cells is critical for NASH initiation and development of fibrosis in mice, and reflects an infiltration of Th22 cells. Th22 cells are protective in NASH, but only in the absence of IL-17. These data strongly support the potentiality of clinical applications of IL-17 inhibitors that can prevent NASH by both abolishing the lipotoxic action of IL-17 and allowing IL-22-mediated protection.